{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:36:06Z","timestamp":1787020566863,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Mol Allergy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologics are currently one of the main treatment options for a number of diseases. The IgG4 monoclonal antibody dupilumab targets the Interleukin-4 receptor alpha chain, thus preventing the biological effects of the cytokines IL-4 and IL-13, that are essential for the Th2 response. Several controlled trials showed that dupilumab is effective and safe in patients with atopic dermatitis (AD), severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), thus resulting in approval by regulatory agencies. Aim of the study was to evaluate the efficacy and safety of dupilumab in adult patients with CRSwNP stratified by common overlapping comorbid conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a multicenter, observational, prospective study enrolling adult patients with severe CRSwNP who had started dupilumab treatment in the context of standard care from January 2021 to October 2021. Data were collected from twentynine Italian secondary care centers for allergy and clinical immunology, all of which were part of the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). A number of efficacy parameters were used. Patient data were compared using the Wilcoxon test for paired data. All statistical analyses were performed with SPSS version 20 (IBM, Armonk, NY, USA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 82 patients with nasal polyposis were identified. A significant improvement was detected for all the applied efficacy parameters, i.e. 22-item Sino-Nasal Outcome Test (SNOT-22) and bilateral endoscopic nasal polyp score (NPS) scores for CRSwNP, Rhinitis Control Scoring System (RCSS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores for allergic perennial rhinitis, Forced Expiratory Volume in the 1st second (FEV1) and Asthma Quality of Life Questionnaire (AQLQ) scores for asthma, Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) scores for AD. A non-significant improvement was also obtained in the Urticaria Activity Score over 7\u00a0days (UAS7) for chronic spontaneous urticaria. Treatment with dupilumab was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data suggest that dupilumab treatment in patients suffering from CRSwNP and associated comorbidities may be suitable. Such outcome, although confirmation by trials is warranted, suggests the possibility to treat different disorders with a single therapy, with favorable effects especially under the cost-effectiveness aspect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12948-022-00171-2","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T12:04:57Z","timestamp":1652961897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life"],"prefix":"10.1186","volume":"20","author":[{"given":"Eustachio","family":"Nettis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Brussino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Patella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8933-4626","authenticated-orcid":false,"given":"Laura","family":"Bonzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Detoraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Sirufo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Lodi Rizzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelisabetta","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona-Rita","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Ridolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Rolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Brancaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amato","family":"De Paulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Di Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Maria","family":"D\u2019Uggento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Ginaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gaeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Nucera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kliljeda","family":"Jaubashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Villalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Ciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pucciarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Celi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Chieco Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cosmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angiola","family":"Crivellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"D\u2019Al\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"del Biondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Giacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Di Gioacchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Guarnieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stefania","family":"Leto Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Losa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Lucia","family":"Minciullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Passalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliviero","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Schiappoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Baoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristoforo","family":"Incorvaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"issue":"12","key":"171_CR1","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0960327115603594","volume":"34","author":"L Andrews","year":"2015","unstructured":"Andrews L, Ralston S, Blomme E, Barnhart K. A snapshot of biologic drug development: challenges and opportunities. Hum Exp Toxicol. 2015;34(12):1279.","journal-title":"Hum Exp Toxicol"},{"key":"171_CR2","first-page":"1","volume":"23","author":"WJ Fokkens","year":"2012","unstructured":"Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps. Rhinol Suppl. 2012;23:1\u2013299.","journal-title":"Rhinol Suppl"},{"issue":"1","key":"171_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/ijms23010417","volume":"23","author":"F Carsuzaa","year":"2021","unstructured":"Carsuzaa F, B\u00e9quignon E, Dufour X, De Bonnecaze G, Lecron JC, Favot L. Cytokine signature and involvement in chronic rhinosinusitis with nasal polyps. Int J Mol Sci. 2021;23(1):417.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"171_CR4","first-page":"CD013513","volume":"3","author":"LY Chong","year":"2021","unstructured":"Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpottet C, et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2021;3(3):CD013513.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"171_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50(1):5\u201314.","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"171_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jdermsci.2018.01.016","volume":"90","author":"FP Wang","year":"2018","unstructured":"Wang FP, Tang XJ, Wei CQ, Xu LR, Mao H, Luo FM. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190\u20138.","journal-title":"J Dermatol Sci"},{"issue":"10","key":"171_CR7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1080\/02770903.2018.1520865","volume":"56","author":"Y Zayed","year":"2019","unstructured":"Zayed Y, Kheiri B, Banifadel M, Hicks M, Aburahma A, Hamid K, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2019;56(10):1110\u20139.","journal-title":"J Asthma"},{"key":"171_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","volume":"34","author":"C Hopkins","year":"2009","unstructured":"Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngol. 2009;34:447\u201354.","journal-title":"Clin Otolaryngol"},{"key":"171_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","volume":"124","author":"M Schatz","year":"2009","unstructured":"Schatz M, Kosinski M, Yarlas A, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the asthma control test. J Allergy Clin Immunol. 2009;124:719\u201323.","journal-title":"J Allergy Clin Immunol"},{"key":"171_CR10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper EF, O\u2019Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902\u20137.","journal-title":"Eur Respir J"},{"key":"171_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","volume":"99","author":"EF Juniper","year":"2005","unstructured":"Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553\u20138.","journal-title":"Respir Med"},{"key":"171_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","volume":"47","author":"EF Juniper","year":"1994","unstructured":"Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81\u20137.","journal-title":"J Clin Epidemiol"},{"key":"171_CR13","unstructured":"Initiative for Asthma G. Global Strategy for Asthma Management and Prevention; 2016. www. ginasthma.org."},{"key":"171_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaad.2003.08.003","volume":"50","author":"JM Hanifin","year":"2004","unstructured":"Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)\/American Academy of Dermatology Association \u2018\u201cAdministrative Regulations for Evidence-Based Clinical Practice Guidelines.\u201d\u2019 J Am Acad Dermatol. 2004;50:391\u2013404.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"171_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.18176\/jiaci.0519","volume":"30","author":"E Nettis","year":"2020","unstructured":"Nettis E, Ortoncelli M, Pellacani G, Foti C, Di Leo E, Patruno C, et al. A Multicenter study on the prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis. J Investig Allergol Clin Immunol. 2020;30(6):448\u201350.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"171_CR16","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/jdv.15350","volume":"33","author":"AV Marzano","year":"2019","unstructured":"Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2019;33(5):918\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"171_CR17","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1034\/j.1398-9995.2001.00296.x","volume":"56","author":"E Nettis","year":"2001","unstructured":"Nettis E, Dambra P, Loria MP, Cenci L, Vena GA, Ferrannini A, et al. Mast-cell phenotype in urticaria. Allergy. 2001;56(9):915.","journal-title":"Allergy"},{"issue":"1","key":"171_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12931-019-1065-3","volume":"20","author":"XF Xiong","year":"2019","unstructured":"Xiong XF, Zhu M, Wu HX, Fan LL, Cheng DY. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. Respir Res. 2019;20(1):108.","journal-title":"Respir Res"},{"issue":"11","key":"171_CR19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00106-021-01018-z","volume":"69","author":"L Klimek","year":"2021","unstructured":"Klimek L, Chaker A, Deitmer T, Plontke SK, Wollenberg B, Bousquet J, et al. Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps. HNO. 2021;69(11):868\u201377.","journal-title":"HNO"},{"issue":"3","key":"171_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","volume":"140","author":"Y Han","year":"2017","unstructured":"Han Y, Chen Y, Liu X, Zhang J, Su H, Wen H, et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2017;140(3):888\u201391.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"171_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40257-017-0324-7","volume":"19","author":"I Snast","year":"2018","unstructured":"Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145\u201365.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"171_CR22","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/jdv.17351","volume":"35","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797\u2013810.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"171_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139\u201347.","journal-title":"J Am Acad Dermatol"},{"key":"171_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","volume":"54","author":"Z Ou","year":"2018","unstructured":"Ou Z, Chen C, Chen A, Yang Y, Zou W. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303\u201310.","journal-title":"Int Immunopharmacol"},{"key":"171_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","volume":"19","author":"P Fleming","year":"2018","unstructured":"Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;19:62\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"171_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/all.14610","volume":"76","author":"X Chen","year":"2021","unstructured":"Chen X, Liu M, Wu S, Huang Z, Li X, Lai X, et al. Treatment-emergent adverse events in dupilumab-treated patients with allergic diseases: a meta-analysis. Allergy. 2021;76(2):593.","journal-title":"Allergy"},{"issue":"2","key":"171_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4168\/aair.2021.13.2.347","volume":"13","author":"E Nettis","year":"2021","unstructured":"Nettis E, Patella V, Brancaccio R, Detoraki C, Di Leo E, Incorvaia C, et al. Efficacy of dupilumab in concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyps: a preliminary study. Allergy Asthma Immunol Res. 2021;13(2):347\u20139.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"4","key":"171_CR28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/jdv.17094","volume":"35","author":"C Patruno","year":"2021","unstructured":"Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G, Dupilumab for Atopic Dermatitis of the Elderly study group, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021;35(4):958\u201364.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"171_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/cea.13614","volume":"50","author":"C Dupin","year":"2020","unstructured":"Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789\u201398.","journal-title":"Clin Exp Allergy"},{"issue":"10","key":"171_CR30","first-page":"979","volume":"69","author":"M Yamamoto","year":"2020","unstructured":"Yamamoto M, Okuno M, Sasaki T, Fujimoto R, Kataoka Y, Kawashima K. Effects of dupilumab on perennial allergic rhinitis in atopic dermatitis patients. Arerugi. 2020;69(10):979\u201388.","journal-title":"Arerugi"},{"issue":"10","key":"171_CR31","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1111\/all.14338","volume":"75","author":"E Nettis","year":"2020","unstructured":"Nettis E, Patella V, Lombardo C, Detoraki A, Macchia L, Di Leo E, et al. Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis. Allergy. 2020;75(10):2653\u201361.","journal-title":"Allergy"},{"issue":"2","key":"171_CR32","volume":"34","author":"E Errichetti","year":"2021","unstructured":"Errichetti E, Stinco G. Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review. Dermatol Ther. 2021;34(2): e14821.","journal-title":"Dermatol Ther"},{"issue":"5","key":"171_CR33","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","volume":"7","author":"JK Lee","year":"2019","unstructured":"Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7(5):1659\u20132166.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"171_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):1\u201313.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"171_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s13555-017-0201-6","volume":"7","author":"A Kuznik","year":"2017","unstructured":"Kuznik A, B\u00e9go-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, et al. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther (Heidelb). 2017;7(4):493\u2013505.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"171_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.anai.2019.07.004","volume":"123","author":"CD Codispoti","year":"2019","unstructured":"Codispoti CD, Mahdavinia M. A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol. 2019;123(3):232\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"Suppl 1","key":"171_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.aller.2017.09.012","volume":"45","author":"S Quirce","year":"2017","unstructured":"Quirce S, Phillips-Angles E, Dom\u00ednguez-Ortega J, Barranco P. Biologics in the treatment of severe asthma. Allergol Immunopathol (Madr). 2017;45(Suppl 1):45\u20139.","journal-title":"Allergol Immunopathol (Madr)"}],"container-title":["Clinical and Molecular Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12948-022-00171-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12948-022-00171-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12948-022-00171-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T12:06:55Z","timestamp":1652962015000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalmolecularallergy.biomedcentral.com\/articles\/10.1186\/s12948-022-00171-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["171"],"URL":"https:\/\/doi.org\/10.1186\/s12948-022-00171-2","relation":{},"ISSN":["1476-7961"],"issn-type":[{"value":"1476-7961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (#75\/21) was approved by the ethical committee of Naples University Hospital, Italy. Informed consent was obtained from all patients who agreed to participate to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PP: GSK, Novartis (fees for lectures), LeoPharma (expert board); DB: GSK, Novartis, Astra, Sanofi (speaker); MC: GSK, Sanofi (speaker); EH: Sanofi, Regeneron, Novqrtis, GSK, Astrazeneca, Circassia, Stallergenes-Greer, Nestl\u00e8 Purina (speaker and advisory board), AD: Sanofi, Glaxo-Smith Kline (advisory board), SDG: AstraZeneca, GSK, Novartis, Sanofi (advisory board and speaker). EN, LB, VP, LB, EDL, MMS, MT, ER, LM, GR, RB, GS, DDB, ADP, FCB, AMD, CC, CL, LG, MDG, KJ, EN, LD, DC, GG, FG, GS, DV, FLR, GP, FP, GC, LC, MTC, MAC, SD, PDB, LDP, EF, SG, MSLB, FL, AM, MRY, PLM, SP, OR, LS, MS, AV, AV, YB, CI, GWC have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}